Federal securities regulators are asking questions about an Ocular Therapeutics eye pain product that was rejected by the FDA in July.
Ocular (NASDAQ: OCUL) received a subpoena from the Securities and Exchange Commission dated Dec. 15, the Bedford, MA, company said Friday after the markets closed. The subpoena seeks documents and information regarding the company’s lead product candidate, Dextenza. In a news release, Ocular characterized the SEC communication as a “non-public, fact-finding inquiry.”
The company gave no details about what the SEC was asking, though it did say that the regulator’s inquiry covers communications with the FDA, investors, and unspecified… Read more »
UNDERWRITERS AND PARTNERS